BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BioCryst Pharma (BCRX) PT Raised to $11 at Jefferies
August 5, 2024 4:01 PM EDTJefferies analyst Maury Raycroft raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $11.00 (from $10.00) while maintaining a Buy rating.
The analyst comments "Focus heading into 2Q was on Orladyo sales, and BCRX delivered another commercial surprise (stock +5.5%) and increased guidance due to... More
